Sign In
Buy NVST
$22.40
-0.540 (-2.35%)
At Close: Jun 03, 2026
Earnings Preview: NanoString Technologies (NSTG) Q2 Earnings Expected to Decline
02:03pm, Thursday, 28'th Jul 2022 Zacks Investment Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for
02:02pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Analysts Have This to Say About Envista Holdings
09:35pm, Wednesday, 20'th Jul 2022 Benzinga
Analysts have provided the following ratings for Envista Holdings (NYSE:NVST) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
2
0
0
Envista Holdings: Not Sinking My Teeth In Yet
07:33am, Monday, 18'th Jul 2022
Envista Holdings is performing a bit soft from an operational view if you ask me. The company is active on the buy and sell side of M&A here.
Envista Schedules Second Quarter 2022 Earnings Call
04:15pm, Wednesday, 13'th Jul 2022
BREA, Calif. , July 13, 2022 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its second quarter 2022 on Wednesday, August 3, 2022.
Envista (NVST) Q1 Earnings and Revenues Top Estimates
10:45pm, Wednesday, 04'th May 2022 Zacks Investment Research
Envista (NVST) delivered earnings and revenue surprises of 6.82% and 0.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista Holdings Corp (NVST) CEO Amir Aghdaei on Q1 2022 Results - Earnings Call Transcript
08:32pm, Wednesday, 04'th May 2022
Envista Holdings Corp, Inc. (NYSE:NVST ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Stephen Keller - Vice President, Investor Relations Amir Aghdaei - President, CEO
Envista (NVST) Q1 Earnings and Revenues Top Estimates
08:18pm, Wednesday, 04'th May 2022
Envista (NVST) delivered earnings and revenue surprises of 6.82% and 0.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
09:45pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Expert Ratings For Envista Holdings
03:01pm, Monday, 04'th Apr 2022 Benzinga
Envista Holdings (NYSE:NVST) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
3
1
0
0
Last 3
Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish
03:56pm, Tuesday, 22'nd Feb 2022 Zacks Investment Research
The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat
05:16pm, Monday, 21'st Feb 2022 Zacks Investment Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down
02:19pm, Friday, 18'th Feb 2022 Zacks Investment Research
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up
02:18pm, Friday, 18'th Feb 2022 Zacks Investment Research
Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.
